Drug intelligence / Profile preview

escitalopram + fluoxetine + methylphenidate

Development stage
Unknown
Lead developer
Lundbeck
Modality
Small Molecules
Administration
Oral, Transdermal
01

Overview

This is a combination of three pharmaceutical drugs—escitalopram, fluoxetine, and methylphenidate. Escitalopram and fluoxetine are both selective serotonin reuptake inhibitors (SSRIs) used primarily to treat depression and anxiety disorders by increasing serotonin levels in the brain through inhibition of its reuptake at the synaptic cleft. Methylphenidate is a central nervous system stimulant commonly prescribed for attention-deficit/hyperactivity disorder (ADHD) and narcolepsy; it works mainly by inhibiting dopamine and norepinephrine reuptake, thereby increasing their concentrations in the synaptic cleft. While combinations of an SSRI with methylphenidate are sometimes used clinically for patients with comorbid ADHD and depression, there is no established clinical precedent or approval for combining two SSRIs (escitalopram plus fluoxetine) together with methylphenidate due to overlapping mechanisms, increased risk of adverse effects such as serotonin syndrome, QT prolongation, or other pharmacodynamic interactions[1][2][3][4][6][8]. The safety profile of combining one SSRI with methylphenidate has been studied; however, triple therapy involving two SSRIs plus a stimulant lacks evidence for efficacy or safety.

02

Targets

SERT (Sodium-dependent serotonin transporter)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on escitalopram + fluoxetine + methylphenidate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on escitalopram + fluoxetine + methylphenidate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call